NCT01616134

Brief Summary

Korean red ginseng (KRG) is popular worldwide since it is believed to contain ingredients with a variety of health enhancement effects. Several in vitro studies and animal studies showed that ginseng has anti-obesity, anti-diabetic and anti-metabolic disease effects. Several studies involving type 2 diabetes mellitus (T2DM) patients reported that administration of KRG for 12 weeks resulted in positive effects on the maintenance of sugar control effect and improvement of insulin resistance Although there is evidence to suggest that KRG could efficacious reduction in postprandial glycemia, the benefits of long-term KRG in healthy individuals on insulin sensitivity has not yet been established. Therefore, we investigated whether KRG affected insulin sensitivity in healthy overweight or obese Korean subjects without overt diabetes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2010

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2011

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

June 5, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 11, 2012

Completed
Last Updated

March 3, 2017

Status Verified

March 1, 2017

Enrollment Period

8 months

First QC Date

June 5, 2012

Last Update Submit

March 1, 2017

Conditions

Keywords

overweight,ginseng

Outcome Measures

Primary Outcomes (1)

  • insulin sensitivity (insulin, HOMA-IR, QUICKI)

    Blood samples after a 12-h fast were taken at baseline and 12 weeks after randomization. Blood samples were taken after at least 8 hours of fasting for glucose, insulin, liver enzyme, creatinine and lipid test. The homeostasis model assessment index-insulin resistance (HOMA-IR) was calculated using a fomula: \[fasting plasma insulin (µU/mL) × fasting plasma glucose (mg/dL)\] / (22.5×18.182) and quantitative insulin-sensitivity check index (QUICKI) was calculated using a formula: 1 / \[log fasting insulin (µU/mL) + log fasting blood sugar (mg/dL)\]

    12 weeks

Study Arms (2)

Korea Red Ginseng

ACTIVE COMPARATOR

Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.

Other: Korea red ginseng

placebo contating constarch

PLACEBO COMPARATOR
Other: Placebo

Interventions

Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks

Korea Red Ginseng
PlaceboOTHER

The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.

placebo contating constarch

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ages of 20 and 60 years
  • BMI ≥ 23 kg/m2

You may not qualify if:

  • any supplements or medications, including anti-diabetic drugs, anti-hypertensive drugs, steroids, or hormonal products, during the previous 4 weeks
  • participant's systolic BP was above 140 mmHg or diastolic BP above 90 mmHg
  • above 100 m/dL before enrollment in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, 626-770, South Korea

Location

MeSH Terms

Conditions

Insulin ResistanceObesityOverweight

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Pusan national iniversity Yangsan Hospital

Study Record Dates

First Submitted

June 5, 2012

First Posted

June 11, 2012

Study Start

August 1, 2010

Primary Completion

April 1, 2011

Study Completion

April 1, 2011

Last Updated

March 3, 2017

Record last verified: 2017-03

Locations